243 related articles for article (PubMed ID: 15677447)
1. Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction.
Novotny-Diermayr V; Lin B; Gu L; Cao X
J Biol Chem; 2005 Apr; 280(13):12747-57. PubMed ID: 15677447
[TBL] [Abstract][Full Text] [Related]
2. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
3. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
[TBL] [Abstract][Full Text] [Related]
4. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130.
Schmitz J; Weissenbach M; Haan S; Heinrich PC; Schaper F
J Biol Chem; 2000 Apr; 275(17):12848-56. PubMed ID: 10777583
[TBL] [Abstract][Full Text] [Related]
5. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Kim H; Baumann H
Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
[TBL] [Abstract][Full Text] [Related]
6. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling.
Fischer P; Lehmann U; Sobota RM; Schmitz J; Niemand C; Linnemann S; Haan S; Behrmann I; Yoshimura A; Johnston JA; Müller-Newen G; Heinrich PC; Schaper F
Biochem J; 2004 Mar; 378(Pt 2):449-60. PubMed ID: 14611646
[TBL] [Abstract][Full Text] [Related]
7. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130.
Lehmann U; Schmitz J; Weissenbach M; Sobota RM; Hortner M; Friederichs K; Behrmann I; Tsiaris W; Sasaki A; Schneider-Mergener J; Yoshimura A; Neel BG; Heinrich PC; Schaper F
J Biol Chem; 2003 Jan; 278(1):661-71. PubMed ID: 12403768
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation.
Anhuf D; Weissenbach M; Schmitz J; Sobota R; Hermanns HM; Radtke S; Linnemann S; Behrmann I; Heinrich PC; Schaper F
J Immunol; 2000 Sep; 165(5):2535-43. PubMed ID: 10946280
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C delta associates with the interleukin-6 receptor subunit glycoprotein (gp) 130 via Stat3 and enhances Stat3-gp130 interaction.
Novotny-Diermayr V; Zhang T; Gu L; Cao X
J Biol Chem; 2002 Dec; 277(51):49134-42. PubMed ID: 12361954
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells.
Kim H; Hawley TS; Hawley RG; Baumann H
Mol Cell Biol; 1998 Mar; 18(3):1525-33. PubMed ID: 9488469
[TBL] [Abstract][Full Text] [Related]
11. The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction.
Schmitz J; Dahmen H; Grimm C; Gendo C; Müller-Newen G; Heinrich PC; Schaper F
J Immunol; 2000 Jan; 164(2):848-54. PubMed ID: 10623831
[TBL] [Abstract][Full Text] [Related]
12. Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2.
Fairlie WD; De Souza D; Nicola NA; Baca M
Biochem J; 2003 Jun; 372(Pt 2):495-502. PubMed ID: 12593670
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.
Heinrich PC; Behrmann I; Müller-Newen G; Schaper F; Graeve L
Biochem J; 1998 Sep; 334 ( Pt 2)(Pt 2):297-314. PubMed ID: 9716487
[TBL] [Abstract][Full Text] [Related]
15. Different protein turnover of interleukin-6-type cytokine signalling components.
Siewert E; Müller-Esterl W; Starr R; Heinrich PC; Schaper F
Eur J Biochem; 1999 Oct; 265(1):251-7. PubMed ID: 10491180
[TBL] [Abstract][Full Text] [Related]
16. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.
Sum EY; Peng B; Yu X; Chen J; Byrne J; Lindeman GJ; Visvader JE
J Biol Chem; 2002 Mar; 277(10):7849-56. PubMed ID: 11751867
[TBL] [Abstract][Full Text] [Related]
17. Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase.
Giordano V; De Falco G; Chiari R; Quinto I; Pelicci PG; Bartholomew L; Delmastro P; Gadina M; Scala G
J Immunol; 1997 May; 158(9):4097-103. PubMed ID: 9126968
[TBL] [Abstract][Full Text] [Related]
18. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Podewski EK; Hilfiker-Kleiner D; Hilfiker A; Morawietz H; Lichtenberg A; Wollert KC; Drexler H
Circulation; 2003 Feb; 107(6):798-802. PubMed ID: 12591746
[TBL] [Abstract][Full Text] [Related]
19. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.
Hermanns HM; Radtke S; Haan C; Schmitz-Van de Leur H; Tavernier J; Heinrich PC; Behrmann I
J Immunol; 1999 Dec; 163(12):6651-8. PubMed ID: 10586060
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
